LOQTORZI® net revenue more than doubled to $40.8 million in 2025 from $19.1 million in 2024 –– Reduced secured and convertible debt by 90% from ...

AC Immune Initiates Phase 1 Clinical Trial of NLRP3 Inhibitor ACI-19764 is an orally available highly brain-penetrant small molecule NLRP3 ...

Novo Nordisk NVO shares have plunged 22% in the past month, wiping out nearly $50 billion in market capitalization. Following ...

Findings from a study analyzing 36 high-intent business search terms identified the industries facing the highest barriers to organic search visibility on Google in 2026. The study from Social Market ...

TD Cowen 46th Annual Health Care Conference March 4, 2026 10:30 AM ESTCompany ParticipantsBrian Sullivan - Co-Founder, Chairman ...

BBO-11818 is a selective, orally bioavailable non-covalent inhibitor that targets KRAS in both the ON and OFF states, has ...

The "Head and Neck Cancer Therapeutics Market – Growth, Share, Opportunities & Competitive Analysis, 2024 – 2032" report has ...

Transformative clinical pipeline transaction will add CL-273, a pan-EGFR inhibitor, and CL-741, a Phase 1-Ready c-MET inhibitor, to Kairos Pharma's clinical portfolio to target multi-billion dollar ...

The Hematologic Malignancies Market is projected to grow from USD 72,200.85 million in 2024 to USD 128,481.41 million by 2032 ...

Jay Bregman, CEO and co-founder of Andel discusses how FDA’s planned action against non-FDA-approved GLP-1 products could reshape competition in obesity and diabetes care. In a conversation with ...